MDM2-siRNA靶向阻断对骨肉瘤抑制作用的实验研究
摘要
目的观察靶向MDM2的小干扰RNA(siRNA)对骨肉瘤生长的影响。方法1、应用免疫组化方法检测MDM2在人骨肉瘤组织的表达;2、以MDM2已知序列为靶点,构建PGCsilencer~(TM)-MDM2 siRNA重组质粒;3、通过体外、体内实验,研究重组质粒转染骨肉瘤U20细胞及裸鼠瘤内注射重组质粒后MDM2的表达情况及细胞凋亡情况。结果1、免疫组织化学研究结果提示MDM2的过度表达在骨肉瘤的发生、发展过程中起重要作用。2、成功地构建了PGCsilencer~(TM)-MDM2 siRNA重组质粒,为进一步研究MDM2结构与功能及RNAi技术的应用提供了方便条件。3、成功地将重组质粒转染入骨肉瘤U20细胞,为后续的研究工作作好了铺垫。4、PGCsilencer~(TM)-MDM2 siRNA重组质粒转染U20骨肉瘤细胞后MDM2的表达无论在蛋白水平还是在基因水平上都明显下调,体外研究结果证实,RNA干涉MDM2基因的效果具有特异性和高效性。5、成功地建立了骨肉瘤裸鼠动物模型:通过体内实验,证实瘤内注射PGCsilencer~(TM)-MDM2 siRNA重组质粒且应用电穿孔技术可明显抑制裸鼠骨肉瘤的生长,降低肿瘤体积及重量。结果显示,MDM2的表达明显受抑,且促进了细胞的凋亡及肿瘤组织坏死。结论应用RNAi技术沉默MDM2基因可以降低骨肉瘤细胞中MDM2的表达,导致细胞凋亡进而抑制肿瘤的生长。
Osteosarcoma is the most common type of malignant bone cancer in the young people,and deeply threatens the health and life quality.Therefore it becomes a very important region in studying the mechanism of malignant cancer evolution,searching the novel effective methods of diagnosis and therapy and clerifying the theory basis of improving prognosis,with the completion of large-scale genome sequencing,thousands of genes have been identified,and we know nothing about their function.The overexpression of oncogenes are genomic features of human cancers.Inhihition of abnormal expression of there oncogenes has been a commom idea for development of the malignant therapy.Some research has been testified that MDM2 existed in osteosarcoma and signal conduction path was related with cell's proliferation.It has been identified that RNA interference signaling techology is amore powerful tool.Investigate the inhibitory effect of the small interfering RNA targeting on MDM2 gene,on the growth of osteosarcoma in this study.
The human homologue of the murine double minute 2 gene (MDM2),a p53-binding protein which may act as a regulator of p53 protein function,has recently been cloned.Initial studies of this gene in a variety of human tumors have shown frequent gene amplification in most types of sarcomas, including osteosarcomas.Amplification of the MDM2 gene may produce a functional inactivation of the p53 protein.To examine possible clinical or pathological correlates of MDM2 gene amplification in osteosarcoma,MDM2 gene amplification may be associated with tumor progression and metastasis in osteosarcoma.Further investigation is warranted on the potential clinicopathological correlates of MDM2 gene amplification in osteosarcoma.
The p53 gene is the most frequently altered gene in human malignancies and has also been implicated in the development of a number of companion animal tumours.One mechanism by which mdm2 may down regulate p53,is to target p53 for degradation.The p53 protein is maintained in normal cells as an unstable protein,and its interaction with p53 can target p53 for degradation via a ubiquitin proteosome pathway.MDM2 can also control p53 function by suppressing p53 transcriptional activity.MDM2 is a transcriptional target of p53 and expression is induced by the binding of p53 to an internal promoter within the MDM2 gene.MDM2 can in turn bind to a domain within the amino terminus of p53 thereby inhibiting the transcriptional activity and G1 arrest function of p53 by masking access to the transcriptional machinery.Gene amplification of MDM2 has been found almost exclusively in human sarcomas and suggests that this is an alternative mechanism for inactivating p53 in these tumours.
The p53 protein is maintained in normal cells as an unstable protein,and its interaction with p53 can target p53 for degradation via a ubiquitin proteosome pathway.MDM2 can also control p53 function by suppressing p53 transcriptional activity.MDM2 is a transcriptional target of p53 and expression is induced by the binding of p53 to an internal promoter within the mdm2 gene.
Small interfering RNA(SiRNA),sometimes known as short interfering RNA or silencing RNA.Most notably,siRNA is involved in the RNA interference(RNAi) pathway,where it interferes with the expression of a specific gene.In addition to their role in the RNAi pathway,siRNAs also act in RNAi-related pathways,e.g.,as an antiviral mechanism or in shaping the chromatin structure of a genome;the complexity of these pathways is only now being elucidated. Given the ability to knock down essentially any gene of interest,RNAi via siRNAs has generated a great deal of interest in both basic and applied biology.There are an increasing number of large-scale RNAi screens that are designed to identify the important genes in various biological pathways.Because disease processes also depend on the activity of multiple genes,it is expected that in some situations turning off the activity of a gene with an siRNA could produce a therapeutic benefit
Investigate the inhibitory effect of the small interfering RNA targeting on MDM2 gene,on the growth of osteosarcoma.PGCsilencerTM-MDM2 siRNA was constructed and transfected into the osteosarcoma cell line U20S cell.The inhibition effects on MDM2 were determined by RT-PCR and Western blot analysis.The cellular growth activities were determined by MTT assay,and the cell apoptosis was examined by flow cytometry.The therapeutic effects of siMDM2 was assessed on the nude mouse model of transplanted tumor.The siMDM2 plasmid was successfully constructed.After siMDM2 being transfected into the U20S cells,the expressions of MDM2 gene and protein were significantly inhibited.The ability of cell growth activities decreased greatly and the cell apoptosis occurred apparently.There was no significant difference between the negative,controlled group and non-transfected group.The growth of xenograft tumor in siMDM2 transfected nude mice was inhibited and the expressions of MDM2 gene and protein were down-regulated remarkably.SiRNA targeting MDM2 gene inhibits the MDM2 expression in osteosarcoma U20S cells and the growth of osteosarcoma in nude mice.
In summary,we successfully constructed PGCsilencer TM-MDM2 siRNA plasmid.SiRNA of MDM2 suppressed MDM2 expression in U20 cells,inhibited tumor cells proliferation and increased cell apoptosis significantly.This study demonstrated that in vivo delivery of siRNA into tumor mass results in effective inhibition of expression of gene encoding MDM2 and suppressed growth and induced apoptosis of the cancer cells.MDM2 decresae and wt p53 increase may be provide theory foundation for cancer's prognosis and treatment.Furthermore, RNAi rechnique may be a promising tool for osteosarcoma therapy.
Osteosarcoma is the most common type of malignant bone cancer in the young people,and deeply threatens the health and life quality.Therefore it becomes a very important region in studying the mechanism of malignant cancer evolution,searching the novel effective methods of diagnosis and therapy and clerifying the theory basis of improving prognosis,with the completion of large-scale genome sequencing,thousands of genes have been identified,and we know nothing about their function.The overexpression of oncogenes are genomic features of human cancers.Inhihition of abnormal expression of there oncogenes has been a commom idea for development of the malignant therapy.Some research has been testified that MDM2 existed in osteosarcoma and signal conduction path was related with cell's proliferation.It has been identified that RNA interference signaling techology is amore powerful tool.Investigate the inhibitory effect of the small interfering RNA targeting on MDM2 gene,on the growth of osteosarcoma in this study.
The human homologue of the murine double minute 2 gene (MDM2),a p53-binding protein which may act as a regulator of p53 protein function,has recently been cloned.Initial studies of this gene in a variety of human tumors have shown frequent gene amplification in most types of sarcomas, including osteosarcomas.Amplification of the MDM2 gene may produce a functional inactivation of the p53 protein.To examine possible clinical or pathological correlates of MDM2 gene amplification in osteosarcoma,MDM2 gene amplification may be associated with tumor progression and metastasis in osteosarcoma.Further investigation is warranted on the potential clinicopathological correlates of MDM2 gene amplification in osteosarcoma.
The p53 gene is the most frequently altered gene in human malignancies and has also been implicated in the development of a number of companion animal tumours.One mechanism by which mdm2 may down regulate p53,is to target p53 for degradation.The p53 protein is maintained in normal cells as an unstable protein,and its interaction with p53 can target p53 for degradation via a ubiquitin proteosome pathway.MDM2 can also control p53 function by suppressing p53 transcriptional activity.MDM2 is a transcriptional target of p53 and expression is induced by the binding of p53 to an internal promoter within the MDM2 gene.MDM2 can in turn bind to a domain within the amino terminus of p53 thereby inhibiting the transcriptional activity and G1 arrest function of p53 by masking access to the transcriptional machinery.Gene amplification of MDM2 has been found almost exclusively in human sarcomas and suggests that this is an alternative mechanism for inactivating p53 in these tumours.
The p53 protein is maintained in normal cells as an unstable protein,and its interaction with p53 can target p53 for degradation via a ubiquitin proteosome pathway.MDM2 can also control p53 function by suppressing p53 transcriptional activity.MDM2 is a transcriptional target of p53 and expression is induced by the binding of p53 to an internal promoter within the mdm2 gene.
Small interfering RNA(SiRNA),sometimes known as short interfering RNA or silencing RNA.Most notably,siRNA is involved in the RNA interference(RNAi) pathway,where it interferes with the expression of a specific gene.In addition to their role in the RNAi pathway,siRNAs also act in RNAi-related pathways,e.g.,as an antiviral mechanism or in shaping the chromatin structure of a genome;the complexity of these pathways is only now being elucidated. Given the ability to knock down essentially any gene of interest,RNAi via siRNAs has generated a great deal of interest in both basic and applied biology.There are an increasing number of large-scale RNAi screens that are designed to identify the important genes in various biological pathways.Because disease processes also depend on the activity of multiple genes,it is expected that in some situations turning off the activity of a gene with an siRNA could produce a therapeutic benefit
Investigate the inhibitory effect of the small interfering RNA targeting on MDM2 gene,on the growth of osteosarcoma.PGCsilencerTM-MDM2 siRNA was constructed and transfected into the osteosarcoma cell line U20S cell.The inhibition effects on MDM2 were determined by RT-PCR and Western blot analysis.The cellular growth activities were determined by MTT assay,and the cell apoptosis was examined by flow cytometry.The therapeutic effects of siMDM2 was assessed on the nude mouse model of transplanted tumor.The siMDM2 plasmid was successfully constructed.After siMDM2 being transfected into the U20S cells,the expressions of MDM2 gene and protein were significantly inhibited.The ability of cell growth activities decreased greatly and the cell apoptosis occurred apparently.There was no significant difference between the negative,controlled group and non-transfected group.The growth of xenograft tumor in siMDM2 transfected nude mice was inhibited and the expressions of MDM2 gene and protein were down-regulated remarkably.SiRNA targeting MDM2 gene inhibits the MDM2 expression in osteosarcoma U20S cells and the growth of osteosarcoma in nude mice.
In summary,we successfully constructed PGCsilencer TM-MDM2 siRNA plasmid.SiRNA of MDM2 suppressed MDM2 expression in U20 cells,inhibited tumor cells proliferation and increased cell apoptosis significantly.This study demonstrated that in vivo delivery of siRNA into tumor mass results in effective inhibition of expression of gene encoding MDM2 and suppressed growth and induced apoptosis of the cancer cells.MDM2 decresae and wt p53 increase may be provide theory foundation for cancer's prognosis and treatment.Furthermore, RNAi rechnique may be a promising tool for osteosarcoma therapy.
引文
[1]Michael SC,Cynthia AA,Barrett JC.Regulation of p53stability and actibity in response to genotoxic stress,Muta Res,2000,462:179-188
[2]Oliner JD,Kinzler KW,Meltzer PS,et al.Amplification of a gene encoding a p532associated protein in human sarcomas [J].Nature,1992,358(6381):80-83
[3]PacindaB,Ledet SC,GeodoMM,et al.P 53 and MDM2 immunos2taining in pulmonary blastomas and bronchogenic carcinomas,Human Pathol,1996,27(1):542
[4]Mccamn AH,Kirley A,Carrey DN,et al.Amplification of the MDM2 gene in human breast cancer and its association with MDM2and P53 protein status,Br J Cancer,1995,71(8):981-985.
[5]Lozano G,Montes.MDM2 function,Biochim Biophys Acta,1998,1377(2):55-59
[6]Ladanyi M,Cha C,Lewis R,et al.MDM2 gene amplification in metastatic osteosarcoma,Cancer Res,1993,53(1):16-18
[7]Cordon Cardo C,Latres E,Drobnjak M,et al.Moleculer abnormalities of MDM2 and P53 genes in adult soft tissues,Cancer Res,1994,54:794-796.
[8]肖华亮,陈俐,王东。MDM2蛋白和P53蛋白在骨肉瘤组织中的表达及意义,第三军医大学学报。2000,22(4):357-359
[9]Freedman DA,Wu L,Levine AJ.Functions of the MDM2onco2protein,Cell Mol Life Sci,1999,55(1):96-107.
[10]Hupp T R,Lane D P,Ball KL.Strategies for manipulating the p53 pathway in the treatment of human cancer,Biochem J,2000,352:1217.
[11]Roth J,Dobbelstein.et al.Nucleocytoplasmic shuttling of the mdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus protein,EMBO J,1998,17(2):554-564.
[12]Alarcon Vargas D,Ronai Z.p53-Mdm2 the affair that never ends.Carcinogenesis,2002,23(4):541-547
[13]Meltzer PS.Mdm2 and p53:a question of balance,J Natal Cancer Inst,1994,86(17):1256-1266.
[14]Freedman DA,hevine AJ.Regulation of the p53 protein by the MDM2 oncoprotein-thirty-eighth G.H.A.clowes memorial award lecture,Cancer Res,1999,59(1):1-7
[15]Alkhalaf M,Ganguli G,Messaddeq N,et al.MDM2overexpression generates a skin phenotype in both wild type and p53 null mice.Oncogene,1999,18(7):1419
[16]Callardo D,Drazan KE,McBride WH,Adenovirus based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity.Cancer Res,1996;56(21):4891-4893
[17]Freedman DA,Wu L,Levine AJ.Functions of the MDM2oncoproteion,Cell Mol Life Sci,1999,55(1):96-107.
[18]Fire A et al.Nature,1998;391(6669):806
[19]Elbash ir SM et al.Nature,2001:411(6836):494
[20]Elbash ir SM et al.GenesDev,2001;15(2):188
[21]Cap fen NJ et al.Proc Natl A cad Sci USA,2001;98(17):9742
[22]Boutla A et al.Curr Biol,2001;11(22):1776
[23]郭伟,张志愿.口腔颌面部肿瘤基因治疗的进展.口腔颌面外科杂志,2001,11(增刊)4-6.
[24]Gokgoz N,Wnnder JS,Mousses S,et al.Comparision of P53mutations in patients with localized osteosarcoma and metastatic osteosarcoma,Cancer,2001,92(8):2181-2191.
[25]范凯,王辉,于志红,等.X射线照射诱导鼻咽癌细胞mdrl和p53基因的表达及临床意义,中国肿瘤临床,2006,33(5):260-263
[26]Haupt S,Berger M,Goldberg Z,et al.Apoptosis—the p53network,J cell sci,2003,116(20):4077 4085
[27]吴焱,傅松滨.肿瘤抑制基因在恶性肿瘤基因治疗中的应用,国外医学:遗传学分册,2001,24(1):17
[28]Zamzami N,Brenner C,Marzo I,Susin SA.Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins.Oncogene 16(17):2265-82.
[29]Otake Y,Soundararajan S,Sengupta TK,Kio EA,Smith JC,Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA.Blood 109(7):3069-75
[30]杨家驹,段振铃.肿瘤的基因治疗进展,医学综述,2005,11(10):883-885
[31]Chao DT,Korsmeyer SJ,BCL-2 family:regulators of cell death,Annu.Rev.Immunol.16:395-419.
[32]Sakurada A,Hamada H,Fukushige S,et al.Adenovirus mediated delivery of the PTEN gene inhibits cell growth by induction of apoptosis in endometrial cancer,Int J Oncol,1999,15(6):1069-1074
[33]Madreperla S A,Whittum Hudson J A,Prendergast R A,et al.Intraocular tumor suppression of retinoblastoma gene reconstituted retinoblastoma cells,Cancer Res,1991,51(23Pt1):6381-6384
[34]Altieri DC,Molecular cloning of effector cell protease receptor-1,a novel cell surface receptor for the protease factor Xa,Biol.Chem.269(5):3139-42
[35]Caldas H,Jiang Y,Holloway MP,Survivin splice variants regulate the balance between proliferation and cell death, Oncogene 24(12):1994-2007
[36]Yabushita H,Noguchi M,Kinoshita S,et al.Angiostatin expression in endometrial cancer,Oncol Rep,2002,9(6):1193-1196
[37]Hampl M,TanakaT,Albert P S,et al.Therapeutic effects of viral vector mediated antiangiogenic gene transfer in malignant ascites,Hum Gene Ther,2001,12(14):1713-1729.
[38]Altieri DC,Validating survivinas acancer therapeutic target,Nat.Rev.Cancer 3(1):46-54.
[39]李扬,梁惠珍,罗灿峤,等.肉瘤中p53、p21、cyclinA蛋白的表达及其意义,临床与实验病理学杂志,2004,20(5):604-606.
[40]宋海珠,罗荣城,姜波.肿瘤基因治疗的研究进展及展望,解放军医学杂志,2002,27(7):651-652
[41]Isobe M,Emanuel BS,Givol D,Oren M,Croce CM,Localization of gene for human p53 tumour antigen to band 17p13,Nature 320(6057):84-5
[42]华凯,郭庆升,韩壮,吕刚,在骨肉瘤中p18蛋白表达的临床意义,中国医师杂志,2004,11(6):1565-1566
[43]Weber JD,Taylor LJ,Roussel MF,et al,Nucleolar ARF sequesters MDM2 and activates P53,Nat Cell Biol,1999,1(1):20.26
[44]Chevez Barrios P,Chintagumpala M,Mieler W,et al.Response of retinoblastomawith vitreous tumor seeding to adenovirus mediated delivery of thymidine kinase followed by ganciclovir,J Clin 0ncol,2005,23(31):7927-7935.
[45]Pierrefite Carle V,Baque P,Gavelli A,et al.Subcutaneous or intrahepatic injection of suicide gene modified tumour cells induces a systemic antitumour response in a metastatic model of colon carcinoma in rats,Gut,2002,50(3):387-391
[46] Tao, W,Levine, A, Nucleocytoplasmic shuttling of oncoprotein mdm2 is required for Hdm2-mediated degradation of p53, Proc Natl Acad Sci USA 96,3077-3080.
[47] Dilla T, Romero J , Sanstisteban P, et al, The mdm2 proto2onco2 gene sensitizes human medullary thyroid carcinoma cells to ionizing radiation. Oncogene, 2002 ,21(15): 2376-2386
[48] Shieh, S. Y. , Ikeda, M. , Taya, Y , DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2, Cell (91),325-334.
[49] Xue Q ,Sano T , Kashiwabara K, et al.Aberrant expression of pRb , p16 , p14ARF , MDM2 , p21 and p53 in stage I adenocarci2 nomas of the lung, Pathol Int, 2002, 52(2):103-109
[50] Gu L,Findley HW, Zhou M. MDM2 induces NF kappaBPp65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood, 2002, 99(9) : 3367-3375
[51]Giordana MT , Duo D , Gasverde S, et al. MDM2 overexpression is associated with short survival in adults with medulloblastoma. Neuroncol ,2002,4(2) :115-122
[52] Wang H , Nan L ,Yu D,et al. Anti-tumor efficacy of a novel anti-sense anti-MDM2 mixed2backbone oligonucleotide in human colon cancer models : p53-dependent and p53-independent mechanisms.Mol Med ,2002,8 (4):185-199
[53] Prasad G, Wang H , Agrawal S , et al. Antisense anti-MDM2 oligo-nucleotides as a novel approach to the treatment of glioblastoma multiforme. Anticancer Res ,2002,22 (1A): 107-116
[54] Adams. JM,et al., Science, 1998, 281:1322-1326
[55] Lin HK, Wang L , Hu YC , et al. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by PKB require Mdm2 E3 ligase.EMBO J, 2002,21 (15):4037-4048
[56] Folberg Blum A , Sapir A, Shilo BZ , et al. Overexpression of mouse Mdm2 induces developmental phenotypes in Drosophila, 0ncogene,2002,21(15) :2413-2417
[57] Schlott T, Scharf J G, Gorzel C , et al. Cirrhotic livers reveal genetic changes in the MDM2-P14ARF system of cell cycle regulators,Br J Cancer, 2002, 86(8):1290-1296.
[58] Latonen L, Kurki S, Pitkanen K, et al. P53 and MDM2 are regulated by PI232kinases on multiple levels under stress induced by UV radiation and proteasome dysfunction.Cell Signal, 2003, 15(1) :95-102
[59] Jin Y, Zeng SX , Dai MS, et al. MDM2 inhibits PCAF (p300P CREB-binding protein-associated factor)mediated P53 acetylation, J Biol Chem,2002,277(34):30838-30843
[60] Yin Y, Luciani MG, Fahraeus. P53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products.Nat Cell Biol,2002,4(6):462-467
[61] Blattner C,Hay T,Meek DW,et al, Hypophosphorylation of Mdm2 augments p53 stability,Mol Cell Biol,2002,22(17):6170-6182
[62] De Toledo SM , Azzam EI, Dahlberg WK, et al, ATM complexes with MDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human cells exposed toionizing radiation, Oncogene ,2000,19(54):6185-6193
[63] Khosravi R , Maya R , Gottlieb T ,et al. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci USA , 1999,96(26):14973-14977
[64] Wang X , Zalcenstein A , Oren M. Nitric oxide promotes p53 nuclear retention and sensitizes neuroblastoma cells to apoptosis by ionizing radiation, Cell Death Differ , 2001 (4) : 468-476.
[65] Leung KM , Po LS , Tsang FC , et al. The candidate tumor suppressor ING1b can stabilizes p53 by disrupting the regulation of p53 by MDM2, Cancer Res, 2002,62(17):4890-4893.
[66] Clark PA ,Llanos S , Peters G, Multiple interacting domains contribute to pl4ARF mediated inhibition of MDM2. Oncogene, 2002, 21(29):4498-4507
[67] Gu J , Kawai H , Nie L , et al. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53, J Biol Chem, 2002,277(22):19251-19254
[68]Gokgoz N , Wnnder JS , Mousses S , et al . Comparision of P53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma, Cancer,200,92 (8):2181-2191 [69] Hasegawa T , Hirose T, Seki K, et al . Histological and immunohistochemical diversities and proliferative activity and grading in osteosarcomas, Cancer Detect Prev, 1997,21(3) :280-287
[70] Park YB , Kim HS , Oh J H , et al . The co2expression of P53 protein and glycoprotein is correlated to a poor prognosis in osteosarcoma, Int Orthop,2001,24(6):307-310 [71] Goto A , Kanda H , Ishikawa Y, et al . Association of loss of heterozygosity at the P53 locus with chemoresistance in osteosarcomas, J Cancer Res, 1998,89 (5) :539-547 [72] Asada N , Tsuchiya H , Tomita K. De novo deletions of P53 gene and wild2type P53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line, Anticancer Res, 1999,19(6B):5131-5137
[73] Wang LH, Okaichi K, Ihara M,et al .Sensitivity of an2 ticancer drugs in Saos22 cells transfected with mutant P53 varied with mutation point, Anticancer Res, 1998,18 (1A):321-325
[74] Wang JL , Sun Y, Wu S. Gamma-irradiation induces matrix metalloproteinase II expression in a P53 dependent manner,MolCarcinog,2000,27(4):252-258
[75] Sato N, Mizumoto K, Maehara N ,et al.Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1, Anticancer Res , 2000,20(2A):837-842
[76] Lin J ,Jin X , Page C , et al . A modified P53 overcomes mdm2 mediated oncogenic transformation:a potential cancer therapeuticagent, Cancer Res,2000,60:5895-5901
[77] Bougeret C ,Virone Oddos A ,Adeline E , et al. Cancer gene therapy mediated by CTS1 ,a P53 derivative :advantage over wild-type P53 in growth inhibition of human tumors overexpressing MDM2, Cancer Gene Ther, 20007 (5):789-798
[78] Heessen S, Leonchiks A , Issaeva N , et al . Functional P53 chimeras containing the Epstein-Barr virus Gly2 Ala repeat are protected from Mdm2 and HPV E6 induced proteolysis, Proc Natl Acad Sci USA,2002,99 (3):1532 -1537
[79] Wang X , Michael D , de Murcia G, et a . P53 Activation by nitricoxide involves down-regulation of Mdm2, J Biol Chem ,2002,277(18) : 15697-15702.
[80] Andreu T ,Ebensperger C ,Westphal EM, et al.Self-deleting suicide vectors (SDSV):selective killing of P53 deficient cancer cells, Cancer Res , 2001,61: 6925-6930
[81] Watanabe T ,Sullenger BA. Induction of wild-type P53 activity in human cancer cells by ribozymes that repair mutant P53 transcripts, PNAS,2000,97:8490-8494
[82] Tsuchiya H , Mori Y,Ueda Y, et al .Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type P53 gene in human osteosarcoma,Anticancer Res,200,20(1A):235-242.
[83]Song SU,Boyce FM.Combination treatment for osteosarcoma with baculoviral vector mediated gene therapy(P53) and chemotherapy(adriamycin),Exp Mol Med,2001,33(1):46-53
[84]Densmore CL,Kleinerman ES,Gautam A,et al.Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-P53 complexes,Cancer Gene Ther,2001,8(9):619-627
[85]吴元明,陈苏尼.RNA干涉的最新研究进展.中国生物化学与分子生物学报,2003 19(4)411-417.
[86]张翊,裴德宁.RNA干扰研究进展.中国肿瘤生物治疗杂志,2003,10(1):68-70
[87]Iyer LM,Anantharaman V,Aravind L.Ancient conserved domains shared by animal soluble guanylyl cyclases and bacterial signaling proteins.BMC Genomics,2003,4(1):5.
[88]Brummelkamp TR,Bernards R,Agami R.A system for stable expression of short interfering RNAs in mammalian cells.Science,2002,296(5567):550-553
[89]Irie N,Sakai N,Ueyama T,et al.Subtype-and species-specific knockdown of PKC using short intering RNA.Biochemical and Biophysical Research Communications,2002,298:738-743
[90]Sabine B.Antisense-RNA regulation and RNA interference.Biochemicaet BiophysicaActa,2002,1575(23):15-25
[91]Van RP,BrandAH.Spreding silence with sid.Genome Biol,2004,5(2):208
[92]Lippman Z,May B,Yordan C,et al.Distinct Mechanisms Determine Transposon Inheritance and Methylation via Small Interfering RNA and Histone Modification. PLoS Biol, 2003,1(3): E67
[93] Hall IM, Shankaranarayana GD, Noma K, et al. Establishment and maintenance of a heterochromatin domain. Science, 2002, 297(5590): 2232-2237
[94]Durand-Dubief M, Bastin P. TbAG 1, an Argonaute protein required for RNA interference,is involved in mitosis and chromosome segregation in Trypanosoma brucei, BMC Biol, 2003,1(1): 2.
[95] Heinonen JE, Smith CI, Nore BF. Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). FEBS Lett, 2002, 527(1-3): 274-278
[96] Sui G, SoohooC, Affarei, et al. A DNA vector-based RNA technology to suppress gene expression in mammalian cells. Proc Natl Acal Sci USA, 2002, 99(8): 5515-5520
[97] Clemens JC, Worby CA, Simonson-Leff N, et al. Use of double-stranded RNA interference in Drosophila cell lines to dissect signal transduction pathways. Proc Natl Acad Sci USA,2000, 97(12): 6499-6503
[98] Makimura H, Mizuno TM, Mastaitis JW, et al. Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake. BMC Neurosci, 2002, 3(1): 18
[99] Yang YS, Chen GM, Dong WP, et al. Construction and analysis of activity of an HIV-1/bovine immunodeficiency virus chimeric clone Cdna. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 2003, 17(2): 143-145
[100] Hamasaki K, Nakao K, Matsumoto K, et al. Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett, 2003, 543(1-3): 51-54
[101] Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med, 2003, 9(3): 347-351
[102] Cioca DP, Aoki Y, Kiyosawa K. RNA interference is sfunctional pathway with therapeutic potential in human myeloid leukemia cells lines. Cancer Gene Ther, 2003, 10(2):125-133
[103] Verma UN, Surabhi RM, Schmaltieg A, et al. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res, 2003, 9(4): 1291-1300
[104] Zhang L, Yang N, Mohamed-Hadley A, et al. Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem Biophys Res Commun. 2003, 303(4): 1169-1178
[105] Qiu XB, Markant SL, Yuan J, et al. Nrdp1-mediated degradation of the gigantic IAP, BRUCE, is a novel pathway for triggering apoptosis. EMBO J, 2004 , 2(12): 1
[106] Wang Y, Decker SJ, Sebolt-Leopold J. Knockdown of Chk1,Weel and Mytl by RNA Interference Abrogates G(2) Checkpoint and Induces Apoptosis. Cancer Biol Ther, 2004, 3(3): 1.
[107] Lahav G, Rosenfeld N, Sigal A, et al. Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet, 2004,36: 147-150
[108] Ladanyi M , Cha C , Lewis R , et al. MDM2 gene amplification in metastatic osteosarcoma, Cancer Re ,1993,53 (1):16-18
[109]Yin Y, Stephen CW , L ucianiM G,et al. p53 stability and act ivity is regulated by mdm2 mediated induction of alternative p53 translation products, Nat Cell Bio 1, 2002, 4(6):462-467
[110]Ganguli G,Wasylyk B.p53-independent functions of MDM2.Mol Cancer Res,2003,1:1027-1035
[111]Zietz C,RusleM,Haas C,et al.MDM2 oncoprotein overexpression,p53 gene mutation,and VEGF upregulation in angiosarcomas,Am J Pathol,1998,153(5):1425-1433
[112]Yancopoulos GD,Duvis S,Gale NW,et al.Vascular-specific growth factors and blood vessel formation,Nature,2000,407:242-248
[113]OHTA M,KONNO H,TANAKA T,etal.The significance of circulating vascular endothelial growth factor(VEGF) protein in gastric cancer,Cancer Lett,2003,192(2):215-225
[114]姜海行,刘志明,葛莲英.p53和血管内皮生长因子表达与胃癌血管生成的关系,肿瘤防治杂志,2003,10(2):148-150
[115]Liang Y,Wu J.Epub,p53- dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.J Steroid Biochem Mol Biol,2005,93(2-5):173-182
[116]潘运龙,覃莉,李龙生.肝细胞肝癌中VEGF、P53、mdm2蛋白表达及其相互关系,实用肿瘤杂志,2004,19(4):288-291.
[117]Ravi R,Mookerjee B,Bhujw alla ZM,et al.Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 alpha,Gene Dev,2000,14(1):34-44
[118]Chen YJ,J in YT,Sh ieh DK,et al.Molecular characterization of angiogenic properties of human oral squamous cell carcinoma cells,Oral Onco 1,2002,38(5):699-705
[119]RieskeP,BartkowiakJK,SzadowskaAM,et al.A comparative study of P53/mdm2 genes alterations and P53/mdm2 proteins immunoreactivity in soft-tissue sarcomas,J Exp Clin Cancer Res,1999,18(3):403-416
[120] Ladanyi M , Cha C .Lewis R ,et al. MDM2 gene amplification in metastatic osteosarcoma, Cancer Res, 1993,53(1) : 16-18
[121]Elbashir SM, Harborth J, Weber K, et al . Analysis of gene function in somatic mammalian cells using small interfering RNAs, Methods, 2002, 26 (2) : 199-213.
[122] Fraser A. RNA interference :human genes hit the big screen,Nature , 2004,428(6981):375-378
[123] Shen W G. RNA interference and its current application in mammals, Chin Med J , 2004,117 (7):1084 - 1091
[124]Copson ER, White HE, Blaydes JP,Robinson DO etal, Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers, BMC Cancer.2006, 6(1):80
[125]Lind H,Zienolddiny S,Ekstrom P0,Skaug Y,Haugen A.Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer.Int J Cancer.2006, 2 (22): 24
[126] Freedman DA,Wu L,Levine AJ.Functions of the MDM2 oncoprotein, Cell Mol Life Sci,1999,55 (1):96-107.
[127] Brummelkamp TR.Fabius AW,Mullenders J.Madiredjo M,An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.Nat Chem Biol.2006 ,2(4):202-206
[128] Zhang Z,Wang H,Li M,Rayburn E.Novel MDM2 p53-Independent Functions Identified through RNA Silencing Technologies.Ann N Y Acad Sci. 2005, 10 (11) :205-214.
[129] OLeary KA , Mendrysa SM , Vaccara A , et allMDM2 regulates p53 independently of p19 (ARF) in homeostatic tissues, Mol Cell Biol , 2004 , 24 (1) : 186-191
[130]Rieske P,Bart kowiak J K,Szadowska AM,et al.A comparative study of P53/mdm2 genes alterations and P53/mdm2proteins immunoreactivity in soft tissue sarcomas,Exp Clin Cancer Res,1999,18(3):403-416
[131]Elbashir SM,Harbort h J,Weber K,et al.Analysis of gene function in somatic mammalian cells using small interfering RNAs,Met hods,2002,26(2):199-213.
[132]Copson ER,White HE,Blaydes J P,et al.Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCAI mutation carriers,BMC Cancer,2006,6(1):80-86
[133]Lind H,Zienolddiny S,Ekst rom PO,et al.Association of a functional polymorphism in t he promoter of the MDM2 gene with risk of nonsmall cell lung cancer,Int J Cancer,2006,2(22):24-29
[134]刘晓岚,张学颖,郝明,等.人类MDM2基因多态性与非小细胞肺癌临床症状及病理类型的关联性,吉林大学学报:医学版,2006,32(3):465-469
[135]Shi Y.Mammalian RNAi for the masses,Trends Genet,2003,19(1):9-12
[136]Fraser A.RNA interference:human genes hit the big screen,Nature,2004,428(6981):375-378
[137]Lozano G,Montes de O L R.MDM2 function,Biochim Biophys Acta,1998,1377(2):M55-59
[138]Ladanyi M,Cha C,Lewis R,et al.MDM2 gene amplification in metastatic osteosarcoma,Cancer Res,1993,53(1):16-18
[139]Latres E,Drobnjak M,et al.Moleculer abnormalities of MDM2 and P"genes in adult soft tissues,Cancer Res,1994,54:794-796
[2]Oliner JD,Kinzler KW,Meltzer PS,et al.Amplification of a gene encoding a p532associated protein in human sarcomas [J].Nature,1992,358(6381):80-83
[3]PacindaB,Ledet SC,GeodoMM,et al.P 53 and MDM2 immunos2taining in pulmonary blastomas and bronchogenic carcinomas,Human Pathol,1996,27(1):542
[4]Mccamn AH,Kirley A,Carrey DN,et al.Amplification of the MDM2 gene in human breast cancer and its association with MDM2and P53 protein status,Br J Cancer,1995,71(8):981-985.
[5]Lozano G,Montes.MDM2 function,Biochim Biophys Acta,1998,1377(2):55-59
[6]Ladanyi M,Cha C,Lewis R,et al.MDM2 gene amplification in metastatic osteosarcoma,Cancer Res,1993,53(1):16-18
[7]Cordon Cardo C,Latres E,Drobnjak M,et al.Moleculer abnormalities of MDM2 and P53 genes in adult soft tissues,Cancer Res,1994,54:794-796.
[8]肖华亮,陈俐,王东。MDM2蛋白和P53蛋白在骨肉瘤组织中的表达及意义,第三军医大学学报。2000,22(4):357-359
[9]Freedman DA,Wu L,Levine AJ.Functions of the MDM2onco2protein,Cell Mol Life Sci,1999,55(1):96-107.
[10]Hupp T R,Lane D P,Ball KL.Strategies for manipulating the p53 pathway in the treatment of human cancer,Biochem J,2000,352:1217.
[11]Roth J,Dobbelstein.et al.Nucleocytoplasmic shuttling of the mdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus protein,EMBO J,1998,17(2):554-564.
[12]Alarcon Vargas D,Ronai Z.p53-Mdm2 the affair that never ends.Carcinogenesis,2002,23(4):541-547
[13]Meltzer PS.Mdm2 and p53:a question of balance,J Natal Cancer Inst,1994,86(17):1256-1266.
[14]Freedman DA,hevine AJ.Regulation of the p53 protein by the MDM2 oncoprotein-thirty-eighth G.H.A.clowes memorial award lecture,Cancer Res,1999,59(1):1-7
[15]Alkhalaf M,Ganguli G,Messaddeq N,et al.MDM2overexpression generates a skin phenotype in both wild type and p53 null mice.Oncogene,1999,18(7):1419
[16]Callardo D,Drazan KE,McBride WH,Adenovirus based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity.Cancer Res,1996;56(21):4891-4893
[17]Freedman DA,Wu L,Levine AJ.Functions of the MDM2oncoproteion,Cell Mol Life Sci,1999,55(1):96-107.
[18]Fire A et al.Nature,1998;391(6669):806
[19]Elbash ir SM et al.Nature,2001:411(6836):494
[20]Elbash ir SM et al.GenesDev,2001;15(2):188
[21]Cap fen NJ et al.Proc Natl A cad Sci USA,2001;98(17):9742
[22]Boutla A et al.Curr Biol,2001;11(22):1776
[23]郭伟,张志愿.口腔颌面部肿瘤基因治疗的进展.口腔颌面外科杂志,2001,11(增刊)4-6.
[24]Gokgoz N,Wnnder JS,Mousses S,et al.Comparision of P53mutations in patients with localized osteosarcoma and metastatic osteosarcoma,Cancer,2001,92(8):2181-2191.
[25]范凯,王辉,于志红,等.X射线照射诱导鼻咽癌细胞mdrl和p53基因的表达及临床意义,中国肿瘤临床,2006,33(5):260-263
[26]Haupt S,Berger M,Goldberg Z,et al.Apoptosis—the p53network,J cell sci,2003,116(20):4077 4085
[27]吴焱,傅松滨.肿瘤抑制基因在恶性肿瘤基因治疗中的应用,国外医学:遗传学分册,2001,24(1):17
[28]Zamzami N,Brenner C,Marzo I,Susin SA.Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins.Oncogene 16(17):2265-82.
[29]Otake Y,Soundararajan S,Sengupta TK,Kio EA,Smith JC,Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA.Blood 109(7):3069-75
[30]杨家驹,段振铃.肿瘤的基因治疗进展,医学综述,2005,11(10):883-885
[31]Chao DT,Korsmeyer SJ,BCL-2 family:regulators of cell death,Annu.Rev.Immunol.16:395-419.
[32]Sakurada A,Hamada H,Fukushige S,et al.Adenovirus mediated delivery of the PTEN gene inhibits cell growth by induction of apoptosis in endometrial cancer,Int J Oncol,1999,15(6):1069-1074
[33]Madreperla S A,Whittum Hudson J A,Prendergast R A,et al.Intraocular tumor suppression of retinoblastoma gene reconstituted retinoblastoma cells,Cancer Res,1991,51(23Pt1):6381-6384
[34]Altieri DC,Molecular cloning of effector cell protease receptor-1,a novel cell surface receptor for the protease factor Xa,Biol.Chem.269(5):3139-42
[35]Caldas H,Jiang Y,Holloway MP,Survivin splice variants regulate the balance between proliferation and cell death, Oncogene 24(12):1994-2007
[36]Yabushita H,Noguchi M,Kinoshita S,et al.Angiostatin expression in endometrial cancer,Oncol Rep,2002,9(6):1193-1196
[37]Hampl M,TanakaT,Albert P S,et al.Therapeutic effects of viral vector mediated antiangiogenic gene transfer in malignant ascites,Hum Gene Ther,2001,12(14):1713-1729.
[38]Altieri DC,Validating survivinas acancer therapeutic target,Nat.Rev.Cancer 3(1):46-54.
[39]李扬,梁惠珍,罗灿峤,等.肉瘤中p53、p21、cyclinA蛋白的表达及其意义,临床与实验病理学杂志,2004,20(5):604-606.
[40]宋海珠,罗荣城,姜波.肿瘤基因治疗的研究进展及展望,解放军医学杂志,2002,27(7):651-652
[41]Isobe M,Emanuel BS,Givol D,Oren M,Croce CM,Localization of gene for human p53 tumour antigen to band 17p13,Nature 320(6057):84-5
[42]华凯,郭庆升,韩壮,吕刚,在骨肉瘤中p18蛋白表达的临床意义,中国医师杂志,2004,11(6):1565-1566
[43]Weber JD,Taylor LJ,Roussel MF,et al,Nucleolar ARF sequesters MDM2 and activates P53,Nat Cell Biol,1999,1(1):20.26
[44]Chevez Barrios P,Chintagumpala M,Mieler W,et al.Response of retinoblastomawith vitreous tumor seeding to adenovirus mediated delivery of thymidine kinase followed by ganciclovir,J Clin 0ncol,2005,23(31):7927-7935.
[45]Pierrefite Carle V,Baque P,Gavelli A,et al.Subcutaneous or intrahepatic injection of suicide gene modified tumour cells induces a systemic antitumour response in a metastatic model of colon carcinoma in rats,Gut,2002,50(3):387-391
[46] Tao, W,Levine, A, Nucleocytoplasmic shuttling of oncoprotein mdm2 is required for Hdm2-mediated degradation of p53, Proc Natl Acad Sci USA 96,3077-3080.
[47] Dilla T, Romero J , Sanstisteban P, et al, The mdm2 proto2onco2 gene sensitizes human medullary thyroid carcinoma cells to ionizing radiation. Oncogene, 2002 ,21(15): 2376-2386
[48] Shieh, S. Y. , Ikeda, M. , Taya, Y , DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2, Cell (91),325-334.
[49] Xue Q ,Sano T , Kashiwabara K, et al.Aberrant expression of pRb , p16 , p14ARF , MDM2 , p21 and p53 in stage I adenocarci2 nomas of the lung, Pathol Int, 2002, 52(2):103-109
[50] Gu L,Findley HW, Zhou M. MDM2 induces NF kappaBPp65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood, 2002, 99(9) : 3367-3375
[51]Giordana MT , Duo D , Gasverde S, et al. MDM2 overexpression is associated with short survival in adults with medulloblastoma. Neuroncol ,2002,4(2) :115-122
[52] Wang H , Nan L ,Yu D,et al. Anti-tumor efficacy of a novel anti-sense anti-MDM2 mixed2backbone oligonucleotide in human colon cancer models : p53-dependent and p53-independent mechanisms.Mol Med ,2002,8 (4):185-199
[53] Prasad G, Wang H , Agrawal S , et al. Antisense anti-MDM2 oligo-nucleotides as a novel approach to the treatment of glioblastoma multiforme. Anticancer Res ,2002,22 (1A): 107-116
[54] Adams. JM,et al., Science, 1998, 281:1322-1326
[55] Lin HK, Wang L , Hu YC , et al. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by PKB require Mdm2 E3 ligase.EMBO J, 2002,21 (15):4037-4048
[56] Folberg Blum A , Sapir A, Shilo BZ , et al. Overexpression of mouse Mdm2 induces developmental phenotypes in Drosophila, 0ncogene,2002,21(15) :2413-2417
[57] Schlott T, Scharf J G, Gorzel C , et al. Cirrhotic livers reveal genetic changes in the MDM2-P14ARF system of cell cycle regulators,Br J Cancer, 2002, 86(8):1290-1296.
[58] Latonen L, Kurki S, Pitkanen K, et al. P53 and MDM2 are regulated by PI232kinases on multiple levels under stress induced by UV radiation and proteasome dysfunction.Cell Signal, 2003, 15(1) :95-102
[59] Jin Y, Zeng SX , Dai MS, et al. MDM2 inhibits PCAF (p300P CREB-binding protein-associated factor)mediated P53 acetylation, J Biol Chem,2002,277(34):30838-30843
[60] Yin Y, Luciani MG, Fahraeus. P53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products.Nat Cell Biol,2002,4(6):462-467
[61] Blattner C,Hay T,Meek DW,et al, Hypophosphorylation of Mdm2 augments p53 stability,Mol Cell Biol,2002,22(17):6170-6182
[62] De Toledo SM , Azzam EI, Dahlberg WK, et al, ATM complexes with MDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human cells exposed toionizing radiation, Oncogene ,2000,19(54):6185-6193
[63] Khosravi R , Maya R , Gottlieb T ,et al. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci USA , 1999,96(26):14973-14977
[64] Wang X , Zalcenstein A , Oren M. Nitric oxide promotes p53 nuclear retention and sensitizes neuroblastoma cells to apoptosis by ionizing radiation, Cell Death Differ , 2001 (4) : 468-476.
[65] Leung KM , Po LS , Tsang FC , et al. The candidate tumor suppressor ING1b can stabilizes p53 by disrupting the regulation of p53 by MDM2, Cancer Res, 2002,62(17):4890-4893.
[66] Clark PA ,Llanos S , Peters G, Multiple interacting domains contribute to pl4ARF mediated inhibition of MDM2. Oncogene, 2002, 21(29):4498-4507
[67] Gu J , Kawai H , Nie L , et al. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53, J Biol Chem, 2002,277(22):19251-19254
[68]Gokgoz N , Wnnder JS , Mousses S , et al . Comparision of P53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma, Cancer,200,92 (8):2181-2191 [69] Hasegawa T , Hirose T, Seki K, et al . Histological and immunohistochemical diversities and proliferative activity and grading in osteosarcomas, Cancer Detect Prev, 1997,21(3) :280-287
[70] Park YB , Kim HS , Oh J H , et al . The co2expression of P53 protein and glycoprotein is correlated to a poor prognosis in osteosarcoma, Int Orthop,2001,24(6):307-310 [71] Goto A , Kanda H , Ishikawa Y, et al . Association of loss of heterozygosity at the P53 locus with chemoresistance in osteosarcomas, J Cancer Res, 1998,89 (5) :539-547 [72] Asada N , Tsuchiya H , Tomita K. De novo deletions of P53 gene and wild2type P53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line, Anticancer Res, 1999,19(6B):5131-5137
[73] Wang LH, Okaichi K, Ihara M,et al .Sensitivity of an2 ticancer drugs in Saos22 cells transfected with mutant P53 varied with mutation point, Anticancer Res, 1998,18 (1A):321-325
[74] Wang JL , Sun Y, Wu S. Gamma-irradiation induces matrix metalloproteinase II expression in a P53 dependent manner,MolCarcinog,2000,27(4):252-258
[75] Sato N, Mizumoto K, Maehara N ,et al.Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1, Anticancer Res , 2000,20(2A):837-842
[76] Lin J ,Jin X , Page C , et al . A modified P53 overcomes mdm2 mediated oncogenic transformation:a potential cancer therapeuticagent, Cancer Res,2000,60:5895-5901
[77] Bougeret C ,Virone Oddos A ,Adeline E , et al. Cancer gene therapy mediated by CTS1 ,a P53 derivative :advantage over wild-type P53 in growth inhibition of human tumors overexpressing MDM2, Cancer Gene Ther, 20007 (5):789-798
[78] Heessen S, Leonchiks A , Issaeva N , et al . Functional P53 chimeras containing the Epstein-Barr virus Gly2 Ala repeat are protected from Mdm2 and HPV E6 induced proteolysis, Proc Natl Acad Sci USA,2002,99 (3):1532 -1537
[79] Wang X , Michael D , de Murcia G, et a . P53 Activation by nitricoxide involves down-regulation of Mdm2, J Biol Chem ,2002,277(18) : 15697-15702.
[80] Andreu T ,Ebensperger C ,Westphal EM, et al.Self-deleting suicide vectors (SDSV):selective killing of P53 deficient cancer cells, Cancer Res , 2001,61: 6925-6930
[81] Watanabe T ,Sullenger BA. Induction of wild-type P53 activity in human cancer cells by ribozymes that repair mutant P53 transcripts, PNAS,2000,97:8490-8494
[82] Tsuchiya H , Mori Y,Ueda Y, et al .Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type P53 gene in human osteosarcoma,Anticancer Res,200,20(1A):235-242.
[83]Song SU,Boyce FM.Combination treatment for osteosarcoma with baculoviral vector mediated gene therapy(P53) and chemotherapy(adriamycin),Exp Mol Med,2001,33(1):46-53
[84]Densmore CL,Kleinerman ES,Gautam A,et al.Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-P53 complexes,Cancer Gene Ther,2001,8(9):619-627
[85]吴元明,陈苏尼.RNA干涉的最新研究进展.中国生物化学与分子生物学报,2003 19(4)411-417.
[86]张翊,裴德宁.RNA干扰研究进展.中国肿瘤生物治疗杂志,2003,10(1):68-70
[87]Iyer LM,Anantharaman V,Aravind L.Ancient conserved domains shared by animal soluble guanylyl cyclases and bacterial signaling proteins.BMC Genomics,2003,4(1):5.
[88]Brummelkamp TR,Bernards R,Agami R.A system for stable expression of short interfering RNAs in mammalian cells.Science,2002,296(5567):550-553
[89]Irie N,Sakai N,Ueyama T,et al.Subtype-and species-specific knockdown of PKC using short intering RNA.Biochemical and Biophysical Research Communications,2002,298:738-743
[90]Sabine B.Antisense-RNA regulation and RNA interference.Biochemicaet BiophysicaActa,2002,1575(23):15-25
[91]Van RP,BrandAH.Spreding silence with sid.Genome Biol,2004,5(2):208
[92]Lippman Z,May B,Yordan C,et al.Distinct Mechanisms Determine Transposon Inheritance and Methylation via Small Interfering RNA and Histone Modification. PLoS Biol, 2003,1(3): E67
[93] Hall IM, Shankaranarayana GD, Noma K, et al. Establishment and maintenance of a heterochromatin domain. Science, 2002, 297(5590): 2232-2237
[94]Durand-Dubief M, Bastin P. TbAG 1, an Argonaute protein required for RNA interference,is involved in mitosis and chromosome segregation in Trypanosoma brucei, BMC Biol, 2003,1(1): 2.
[95] Heinonen JE, Smith CI, Nore BF. Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). FEBS Lett, 2002, 527(1-3): 274-278
[96] Sui G, SoohooC, Affarei, et al. A DNA vector-based RNA technology to suppress gene expression in mammalian cells. Proc Natl Acal Sci USA, 2002, 99(8): 5515-5520
[97] Clemens JC, Worby CA, Simonson-Leff N, et al. Use of double-stranded RNA interference in Drosophila cell lines to dissect signal transduction pathways. Proc Natl Acad Sci USA,2000, 97(12): 6499-6503
[98] Makimura H, Mizuno TM, Mastaitis JW, et al. Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake. BMC Neurosci, 2002, 3(1): 18
[99] Yang YS, Chen GM, Dong WP, et al. Construction and analysis of activity of an HIV-1/bovine immunodeficiency virus chimeric clone Cdna. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 2003, 17(2): 143-145
[100] Hamasaki K, Nakao K, Matsumoto K, et al. Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett, 2003, 543(1-3): 51-54
[101] Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med, 2003, 9(3): 347-351
[102] Cioca DP, Aoki Y, Kiyosawa K. RNA interference is sfunctional pathway with therapeutic potential in human myeloid leukemia cells lines. Cancer Gene Ther, 2003, 10(2):125-133
[103] Verma UN, Surabhi RM, Schmaltieg A, et al. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res, 2003, 9(4): 1291-1300
[104] Zhang L, Yang N, Mohamed-Hadley A, et al. Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem Biophys Res Commun. 2003, 303(4): 1169-1178
[105] Qiu XB, Markant SL, Yuan J, et al. Nrdp1-mediated degradation of the gigantic IAP, BRUCE, is a novel pathway for triggering apoptosis. EMBO J, 2004 , 2(12): 1
[106] Wang Y, Decker SJ, Sebolt-Leopold J. Knockdown of Chk1,Weel and Mytl by RNA Interference Abrogates G(2) Checkpoint and Induces Apoptosis. Cancer Biol Ther, 2004, 3(3): 1.
[107] Lahav G, Rosenfeld N, Sigal A, et al. Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet, 2004,36: 147-150
[108] Ladanyi M , Cha C , Lewis R , et al. MDM2 gene amplification in metastatic osteosarcoma, Cancer Re ,1993,53 (1):16-18
[109]Yin Y, Stephen CW , L ucianiM G,et al. p53 stability and act ivity is regulated by mdm2 mediated induction of alternative p53 translation products, Nat Cell Bio 1, 2002, 4(6):462-467
[110]Ganguli G,Wasylyk B.p53-independent functions of MDM2.Mol Cancer Res,2003,1:1027-1035
[111]Zietz C,RusleM,Haas C,et al.MDM2 oncoprotein overexpression,p53 gene mutation,and VEGF upregulation in angiosarcomas,Am J Pathol,1998,153(5):1425-1433
[112]Yancopoulos GD,Duvis S,Gale NW,et al.Vascular-specific growth factors and blood vessel formation,Nature,2000,407:242-248
[113]OHTA M,KONNO H,TANAKA T,etal.The significance of circulating vascular endothelial growth factor(VEGF) protein in gastric cancer,Cancer Lett,2003,192(2):215-225
[114]姜海行,刘志明,葛莲英.p53和血管内皮生长因子表达与胃癌血管生成的关系,肿瘤防治杂志,2003,10(2):148-150
[115]Liang Y,Wu J.Epub,p53- dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.J Steroid Biochem Mol Biol,2005,93(2-5):173-182
[116]潘运龙,覃莉,李龙生.肝细胞肝癌中VEGF、P53、mdm2蛋白表达及其相互关系,实用肿瘤杂志,2004,19(4):288-291.
[117]Ravi R,Mookerjee B,Bhujw alla ZM,et al.Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 alpha,Gene Dev,2000,14(1):34-44
[118]Chen YJ,J in YT,Sh ieh DK,et al.Molecular characterization of angiogenic properties of human oral squamous cell carcinoma cells,Oral Onco 1,2002,38(5):699-705
[119]RieskeP,BartkowiakJK,SzadowskaAM,et al.A comparative study of P53/mdm2 genes alterations and P53/mdm2 proteins immunoreactivity in soft-tissue sarcomas,J Exp Clin Cancer Res,1999,18(3):403-416
[120] Ladanyi M , Cha C .Lewis R ,et al. MDM2 gene amplification in metastatic osteosarcoma, Cancer Res, 1993,53(1) : 16-18
[121]Elbashir SM, Harborth J, Weber K, et al . Analysis of gene function in somatic mammalian cells using small interfering RNAs, Methods, 2002, 26 (2) : 199-213.
[122] Fraser A. RNA interference :human genes hit the big screen,Nature , 2004,428(6981):375-378
[123] Shen W G. RNA interference and its current application in mammals, Chin Med J , 2004,117 (7):1084 - 1091
[124]Copson ER, White HE, Blaydes JP,Robinson DO etal, Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers, BMC Cancer.2006, 6(1):80
[125]Lind H,Zienolddiny S,Ekstrom P0,Skaug Y,Haugen A.Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer.Int J Cancer.2006, 2 (22): 24
[126] Freedman DA,Wu L,Levine AJ.Functions of the MDM2 oncoprotein, Cell Mol Life Sci,1999,55 (1):96-107.
[127] Brummelkamp TR.Fabius AW,Mullenders J.Madiredjo M,An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.Nat Chem Biol.2006 ,2(4):202-206
[128] Zhang Z,Wang H,Li M,Rayburn E.Novel MDM2 p53-Independent Functions Identified through RNA Silencing Technologies.Ann N Y Acad Sci. 2005, 10 (11) :205-214.
[129] OLeary KA , Mendrysa SM , Vaccara A , et allMDM2 regulates p53 independently of p19 (ARF) in homeostatic tissues, Mol Cell Biol , 2004 , 24 (1) : 186-191
[130]Rieske P,Bart kowiak J K,Szadowska AM,et al.A comparative study of P53/mdm2 genes alterations and P53/mdm2proteins immunoreactivity in soft tissue sarcomas,Exp Clin Cancer Res,1999,18(3):403-416
[131]Elbashir SM,Harbort h J,Weber K,et al.Analysis of gene function in somatic mammalian cells using small interfering RNAs,Met hods,2002,26(2):199-213.
[132]Copson ER,White HE,Blaydes J P,et al.Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCAI mutation carriers,BMC Cancer,2006,6(1):80-86
[133]Lind H,Zienolddiny S,Ekst rom PO,et al.Association of a functional polymorphism in t he promoter of the MDM2 gene with risk of nonsmall cell lung cancer,Int J Cancer,2006,2(22):24-29
[134]刘晓岚,张学颖,郝明,等.人类MDM2基因多态性与非小细胞肺癌临床症状及病理类型的关联性,吉林大学学报:医学版,2006,32(3):465-469
[135]Shi Y.Mammalian RNAi for the masses,Trends Genet,2003,19(1):9-12
[136]Fraser A.RNA interference:human genes hit the big screen,Nature,2004,428(6981):375-378
[137]Lozano G,Montes de O L R.MDM2 function,Biochim Biophys Acta,1998,1377(2):M55-59
[138]Ladanyi M,Cha C,Lewis R,et al.MDM2 gene amplification in metastatic osteosarcoma,Cancer Res,1993,53(1):16-18
[139]Latres E,Drobnjak M,et al.Moleculer abnormalities of MDM2 and P"genes in adult soft tissues,Cancer Res,1994,54:794-796